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In patients with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer, treatment with trastuzumab has
been shown to markedly improve the outcome. We investigated the role of trastuzumab on brain metastasis (BM) in HER2-positive
breast cancer patients. From 1999 to 2006, 251 patients were treated with palliative chemotherapy for HER2-positive metastatic
breast cancer at Samsung Medical Center. The medical records of these patients were analysed to study the effects of trastuzumab
on BM prevalence and outcomes. Patients were grouped according to trastuzumab therapy: pre-T (no trastuzumab therapy) vs post-
T (trastuzumab therapy). The development of BM between the two treatment groups was significantly different (37.8% for post-T vs
25.0% for pre-T, P¼0.028). Patients who had received trastuzumab had longer times to BM compared with patients who were not
treated with trastuzumab (median 15 months for post-T group vs 10 months for pre-T group, P¼0.035). Time to death (TTD) from
BM was significantly longer in the post-T group than in the pre-T group (median 14.9 vs 4.0 months, P¼0.0005). Extracranial disease
control at the time of BM, 12 months or more of progression-free survival of extracranial disease and treatment with lapatinib were
independent prognostic factors for TTD from BM.
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There has been a steady decline in the death rate from breast
cancer worldwide since 1990. The development of new treatments,
such as a human epidermal growth factor receptor-2 (HER2)-
directed monoclonal antibody, has offered new hope to women
with both early and advanced breast cancer whose tumours
overexpress HER2. However, despite these clinical advances, as
well as advances in our understanding of the related biology,
breast cancer is still the main cause of cancer morbidity and
mortality in women in most countries (Mollick and Carlson, 2004;
Boyle and Ferlay, 2005; Smigal et al, 2006; Korea National
Statistical Office, 2007). In HER2-overexpressing breast cancer,
which is associated with a high recurrence rate and poor outcome
(Slamon et al, 1987; Paik et al, 1990; Kallioniemi et al, 1991; Boss
et al, 2003), trastuzumab-based therapies are well established and
regarded as a standard therapy (Slamon et al, 2001; Pegram et al,
2004). Since the introduction of trastuzumab, different groups
have reported a higher incidence of brain metastases (BMs) in
their patients ranging from 28 to 43% (Bendell et al, 2003; Altaha
et al, 2004; Clayton et al, 2004; Lin et al, 2004; Souglakos et al,
2006; Stemmler et al, 2006; Yau et al, 2006). The biological
explanation for the high incidence of BM may be a greater affinity
of HER2-overexpressing breast cancer for the brain (Ross et al,
2003; Gori et al, 2007; Lin and Winer, 2007). Additionally, it may
be argued that trastuzumab-based therapy prolongs survival to
such an extent that BM, which is known to be a late event in the
course of metastatic cancer, becomes apparent. The higher
incidence of BM could be interpreted as a result of the prolonged
duration of the disease (Stemmler and Heinemann, 2008).
Central nervous system (CNS) metastases, including paren-
chymal and leptomeningeal metastases, are the most common
causes of malignant disease in the brain. Historically, the lack of
durability for CNS control was not a problem for most patients
because BMs occurred late in the course of illness, and progression
in non-CNS was the dominant cause of morbidity and mortality
(Herrero et al, 2004; Bartsch et al, 2007). However, as systemic
therapies improve, the control of CNS disease seems to become
increasingly important for overall disease control.
The purpose of this retrospective study was to analyse how the
addition of trastuzumab to conventional chemotherapies affects
the clinical course of BM in patients with HER2-overexpressing
metastatic breast cancer (MBC), in terms of its biological
behaviour of HER2.
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CNS metastasis among patients with HER2-overexpressing MBC
receiving trastuzumab-based therapy.
PATIENTS AND METHODS
Study design and population
We conducted a retrospective analysis of medical records from
patients with histologically confirmed metastatic or recurrent
breast cancer who received palliative chemotherapy at Samsung
Medical Center from January 1999 to December 2006. All
pathological specimens were reviewed by two experienced
pathologists. HER2 status was evaluated using an antibody (CBII,
Novocastra Laboratories, Newcastle, UK) and fluorescence in situ
hybridisation (FISH). Grade 3 of the HER2 by immunohisto-
chemical (IHC) staining was defined as a positive result for HER2,
and amplification of the HER2 was confirmed by FISH if HER2 was
rated 2þ by IHC. The pre-trastuzumab period (pre-T) was from
1999 to 2002. Most of the patients in this period did not receive
trastuzumab because it was unavailable or not reimbursed by the
Korean medical insurance system for clinical use. We used the
patients in this period as the ‘historical control’. The post-
trastuzumab period (post-T) was from 2003 to 2006. Trastuzumab
was available and reimbursed by the insurance system in Korea for
HER2-overexpressing breast cancer patients during this time period.
Treatment modalities for BMs, either single or combined
modalities, included whole brain radiation therapy (WBRT),
surgical resection, stereotactic radiosurgery (SRS), including
gamma-knife surgery (GKS) and systemic treatments such as
chemotherapy and endocrine therapy. GKS was repeated for
symptomatic control of metastatic brain lesion(s) if possible, with
regular brain MRI follow-ups. Our study protocol was approved by
the institutional review board of Samsung Medical Center.
Statistical analysis
The distant metastasis-free survival (DFS) was defined from the
date of breast cancer diagnosis to the date of documentation of
distant metastasis. The time to BM (TTBM) was defined from the
date of distant metastasis to the date of BM. The time to death
(TTD) from BM was defined from the date of BM to death or the
last follow-up day. The overall survival (OS) was measured from
the first day of treatment for MBC to the date of death or to the last
follow-up day. The progression-free survival (PFS) of extracranial
disease was defined from the first day of last chemotherapy
regimen that had been administered prior to BM, to the date of
progression of systemic disease irrespective of development or
progression of CNS metastases. A switch in chemotherapy after
development or progression of BM was allowed, and was not
regarded as progression of extracranial disease. The brain PFS was
defined from the last date of treatment for CNS metastasis to the
date of progression of any CNS sites. Extracranial disease control
was defined as systemic disease status, except in the CNS, with
complete response (CR), partial response (PR) or stable disease
(SD) at the time of BM. ‘Only BM’ was defined as absence of
evidence of other distant metastasis except CNS. ‘First metastasis
in brain’ was defined as the presence of brain involvement with or
without systemic metastases when MBC was first documented. The
OS, TTD, DFS, extracranial PFS and brain PFS were estimated by
the Kaplan–Meier product limit method. The log-rank test was
used to compare survival rates. A P-value o0.05 was considered
significant. The differences in characteristics between pre-T and
post-T were estimated by the w
2 test or Fisher’s exact test. A binary
logistic regression analysis was used for the multivariate analysis
of each potential prognostic variable for development. A Cox
proportional hazards regression model was used to assess the
effect of each potential prognostic variable on TTD and OS. All
potential prognostic variables were included in the model, and
variables were removed from this model one at a time in a
backward selection process using the likelihood ratio and a
significance level of 0.05.
RESULTS
Patient population
We identified 857 MBC patients who received palliative
chemotherapy for the treatment of metastatic or recurrent breast
cancer at Samsung Medical Center from 1999 to 2006. Two
hundred sixty-four patients of the 857 patients were confirmed
as HER2-overexpressing breast cancer patients. Among these
patients, 140 patients were not treated with trastuzumab in pre-T
period and 111 patients were treated with trastuzumab in post-T
period. And remaining 13 patients were excluded from the analysis
because of unavailability of their clinical data. Therefore, we
included a total of 251 patients in this study (Figure 1).
Development of brain metastasis
The incidence of BM among the patients in this study was 30.7%
(77 out of 251). The incidence of BM in each treatment group was
25.0% (35 out of 140) in the pre-T group and 37.8% (42 out of 111)
in the post-T group (P¼0.028 by w
2 test).
857 MBC pts who received
palliative chemotherapy identified from database
264 MBC pts
HER2 (+)
593 MBC pts
HER2 (–) or unknown 
140 MBC pts
pre-trastuzumab period
111 MBC pts
post-trastuzumab period
13 MBC pts excluded
because their clinical data 
were unavailable
Figure 1 Patients cohort.
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All 251 patients’ characteristics are summarised in Table 1. The
median age of the entire population was 48 (range 25–77).
Common metastatic sites were lung (57.0%), bone (50.8%), lymph
nodes (37.9%), liver (41.7%) and brain (30.7%). There was no
difference between the two groups in terms of metastatic organs,
median age, stage and disease status. Grade III nuclear grades are
more common in post-T group than pre-T group (40.2 vs 58.8%,
P¼0.014).
The patients’ characteristics of 77 HER2-overexpressing
MBC patients at the time of BM are summarised in Table 2.
The number of patients who had three or more metastatic brain
lesions was 28 (80.0%) in the pre-T group and 27 (64.3%) in
the post-T group (P¼0.129). Leptomeningeal seeding had
developed in three pre-T patients (8.6%) and nine post-T patients
(21.4%). There was no significant difference between pre-T and
post-T patients in terms of hormonal receptor status, distribution
of initial TNM staging, pathological grade or performance
status (PS). However, disease control rate of systemic extracranial
lesions (CRþPRþSD) at the time of BM was much higher in
the post-T group (75.6%) than in the pre-T group (48.1%)
(P¼0.020). The ‘only BM’ was more common in pre-T patients
(14.3%) than in post-T patients (2.4%) (P¼0.046). In addition, the
development of the ‘first metastasis in brain’ was also more
common in the pre-T group (25.7%) than in the post-T group
(9.5%) (P¼0.058).
Trastuzumab treatment
Trastuzumab was administered to 27 of the 42 patients with BM
(64.3%) as a first-line treatment with cytotoxic chemotherapy.
Of the remaining 15 patients (35.7%), 10 were treated with
trastuzumab as a second-line therapy, and three were treated with
trastuzumab as a third- or more line therapy. There were 12
patients (28.6%) who had started trastuzumab after development
of BM. Two patients were treated with trastuzumab continuously
before and after BM. The median duration of trastuzumab
treatment was 6.4 (1.2–22.5) months. Lapatinib was also
administered in 10 patients (23.8%) for salvage treatment after BM.
Local and systemic treatment for brain metastasis
Craniotomy was performed in nine patients (11.7%) (8.6% in
pre-T vs 14.3% in post-T, P¼0.437). GKS was more common in
the post-T group (59.5%) than in the pre-T group (28.6%)
(P¼0.007). WBRT was performed in 69 patients (89.6%) (91.4% in
pre-T vs 81.1% in post-T, P¼0.633). Systemic chemotherapy was
delivered to 45 patients (58.4%) and the median number of the
systemic chemotherapy regimens was 1 (range 0–6). The patients
who were treated with 1 or more systemic chemotherapy regimens
were much more common in the post-T group than in the pre-T
group (57.1 vs 11.4%, Po0.0001). The median number of regimens
delivered to patients was 0 (0–4) in pre-T patients and 2 (0–6)
in post-T patients. The agents used in combination or as single
systemic treatment regimens with or without trastuzumab
after BM were anthracycline, taxane(s), gemcitabine, cisplatin,
capecitabine and vinorelbine.
Table 1 Patient characteristics of 251 HER2-positive metastatic breast
cancer patients
Pre-trastuzumab
group (n¼140)
Post-trastuzumab
group (n¼111)
P-value
(v
2 test)
Age
Median (year, range) 48 (25–77) 48 (25–71) 0.412
ER (+ ve) 63 (45.0%) 41 (36.9%) 0.198
PR (+ ve) 43 (30.9%) 34 (30.6%) 0.959
Disease status
Recurrent 115 (82.1%) 83 (74.89%) 0.155
Initially metastatic 25 (17.9%) 28 (25.2%)
Median DFS (log-rank test) 33.2 months 29.3 months 0.667
Initial TNM stage (n¼239)
I 16 (12.3%) 18 (16.5%) 0.386
II 42 (32.3%) 30 (27.5%)
III 57 (43.8%) 42 (38.5%)
IV 15 (11.5%) 19 (17.4%)
Nuclear grade high
(n¼177)
39 (40.2%) 47 (58.8%) 0.014
Histological grade high
(n¼166)
37 (43.0%) 37 (46.3%) 0.676
Neoadjuvant
chemotherapy (n¼213)
26 (24.3%) 21 (19.8%) 0.430
Adjuvant chemotherapy
(n¼215)
110 (90.2%) 82 (88.2%) 0.640
Adjuvant radiation therapy
(n¼214)
69 (57.0%) 63 (67.7%) 0.110
Metastatic sites
Lymph node (174) 50 (40.0%) 16 (32.7%) 0.529
Liver (n¼240) 48 (37.2%) 52 (46.8%) 0.223
Lung (n¼242) 72 (55.0%) 66 (59.5%) 0.481
Bone (n¼242) 66 (50.4%) 57 (51.4%) 0.651
Brain (n¼251) 35 (25.0%) 42 (37.8%) 0.028
DFS¼distant metastasis-free survival; ER¼oestrogen receptor; PR¼progesterone
receptor.
Table 2 Patient characteristics at the time of BM (n¼77)
Pre-trastuzumab
group (n¼35)
Post-trastuzumab
group (n¼42)
P-value
(v
2 test)
Age
Median (year, range) 44 (25–66) 46 (34–70) 0.145
ER (+ ve) and/or PR (+ ve) 17 (48.6%) 15 (35.7%) 0.254
Disease status
Recurrent 29 (82.8%) 39 (92.9%) 0.144
Initially metastatic 6 (17.2%) 3 (7.1%)
Initial TNM stage (n¼68)
I 2 (6.3%) 3 (7.7%) 0.726
II 17 (53.1%) 17 (43.6%)
III 13 (40.6%) 19 (48.7%)
Nuclear grade high (n¼64) 19 (70.4%) 25 (67.6%) 0.811
Adjuvant chemotherapy
(n¼68)
65 (79.3%) 64 (75.5%) 0.533
Adjuvant radiation therapy
(n¼68)
19 (59.4%) 25 (62.5%) 0.787
DFS X24 months (n¼68) 15 (46.9%) 21 (53.8%) 0.559
Performance status
0–1 22 (62.9%) 30 (71.4%) 0.424
2p 13 (37.1%) 12 (28.6%)
Systemic disease status
CR/PR/SD 13 (48.1%) 31 (75.6%) 0.020
PD 14 (51.9%) 10 (24.4%)
Number of BMs X3 28 (80.0%) 27 (64.3%) 0.129
Leptomeningeal seeding 3 (8.6%) 9 (21.4%) 0.121
Only BM 5 (14.3%) 1 (2.4%) 0.046
First metastasis in brain 9 (25.7%) 4 (9.5%) 0.058
BM¼brain metastasis; CR¼complete response; DFS¼distant metastasis-free
survival; ER¼oestrogen receptor; PD¼progressive disease; PR¼partial response;
PR¼progesterone receptor; SD¼stable disease.
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univariate analysis on TTD
The OS and TTD from development of systemic metastasis
were 26.4 months (95% CI 20.9–31.9) and 9.6 months (95% CI
4.6–14.6), respectively. The OS from development of systemic
metastasis was longer in post-T patients (31.7 months; 95% CI
28.1–35.3) than in pre-T patients (16.7 months; 95% CI 10.3–23.1)
(P¼0.001). 1-year survival rate was significantly higher in post-T
group than in pre-T group (60.0 vs 20.0%, P¼0.001). TTBM was
longer in the post-T group (15 months; 95% CI 12.5–17.5) than in
the pre-T group (10 months; 95% CI 6.1–13.9) with statistical
significance (P¼0.035 by log-rank test) (Figure 2A). TTD
from BM was also significantly longer in the post-T patients
(14.9 months; 95% CI 11.6–18.2) than in the pre-T patients
(4.0 months; 95% CI 2.1–5.9, P¼0.0005) (Figure 2B). In a logistic
regression model, lapatinib treatment (P¼0.049), two or more
systemic chemotherapy regimens after BM (Po0.0001), absence of
‘first metastasis in brain’ (P¼0.045), extracranial disease control
at the time of BM (P¼0.0051) and 12 months or more extracranial
PFS (Po0.0001) were identified as favourable prognostic factors
for survival from BM (Figure 3A and B). 11.9% of the post-T
patients and 37.1% of the pre-T patients died from the progression
of extracranial systemic diseases, mainly lung and liver metastases
(P¼0.014 by Fisher’s exact test) (Table 3).
Cox-regression multivariate analysis of TTD
According to the results of univariate analysis, we performed
Cox-regression multivariate analysis to identify independent
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Figure 2 Brain metastasis outcomes of 77 HER2-overexpressing breast cancer patients with CNS metastasis. (A) Time to brain metastasis (TTBM) from
metastasis; Solid (upper) line represents TTBM of 42 patients with CNS metastasis in the post-trastuzumab period. Median TTMB was 15.0 months (95% CI
12.5–17.5). Dotted (lower) line represents TTMB of 35 patients with CNS metastasis in the pre-trastuzumab period. Median TTMB was 10 months (95% CI
6.1–13.9) (P¼0.035 by log-rank test). (B) Time to death (TTD) from brain metastasis; Solid (upper) line represents TTD of 42 patients with CNS
metastasis in post-trastuzumab period. Median TTMB was 14.9 months (95% CI 11.6–18.2). Dotted (lower) line represents TTMB of 35 patients with CNS
metastasis in pre-trastuzumab period. Median TTMB was 4.0 months (95% CI 2.1–5.9) (P¼0.0005 by log-rank test).
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Figure 3 Kaplan–Meier survival curves of TTD according to extracranial systemic disease control at the time of brain metastasis and TTD according to
the duration of extracranial systemic disease control, except for that in the CNS. (A) TTD according to systemic disease control at the time of brain
metastasis; Solid (upper) line represents TTD of the patients with extracranial systemic disease control (CR or PR or SD) at the time of brain metastasis.
Median TTD was 13.0 months (95% CI 10.6–15.4). Dotted (lower) line represents TTD of the patients without extracranial systemic disease control (PD)
at the time of brain metastasis. Median TTD was 3.6 months (95% CI 1.4–5.8) (P¼0.0051 by log-rank test). (B) TTD according to duration of systemic
disease control, except for that in the CNS; Solid (upper) line represents TTD of the patients with 12 months or more PFS with systemic disease, not
including CNS. Median TTD was 17.0 months (95% CI 14.8–19.2). Dotted (lower) line represents TTD of the patients with less than 12 months PFS of
systemic disease, not including CNS. Median TTD was 4.5 month (95% CI 3.6–5.4) (Po0.0001 by log-rank test).
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regression model used in our study. Lapatinib treatment after BM
(P¼0.040, hazard ratio (HR) 5.069), two or more chemotherapy
regimens after BM (P¼0.001; HR 5.069), ‘first metastasis in brain’
(P¼0.007, HR 10.390), extracranial disease control at the time of
BM (P¼0.009, HR 8.368) and extracranial PFS X12 month
(Po0.0001, HR 26.301) were identified as independent prognostic
factors for favourable survival from BM. Trastuzumab treatment
after BM also showed a high HR, though it did not reach statistical
significance (P¼0.086, HR 3.597).
DISCUSSION
Brain metastases generally occur late in the course of MBC and are
associated with 1- and 2-year survival rates of only 20 and o2%,
respectively, with most patients dying of systemic disease
progression involving the lungs, liver and/or bone (DiStefano
et al, 1979; Tsukada et al, 1983; Patanaphan et al, 1988; Engel et al,
2003). Several studies have examined the effect of HER2 status on
the survival of patients after CNS metastases, and these studies
describe shorter survival times from CNS metastases in patients
with HER2-positive disease who never received trastuzumab
compared with patients with HER2-negative disease (Kirsch
et al, 2005; Tham et al, 2006). Some studies clearly show that
even in the absence of trastuzumab, women with HER2-positive
breast cancer have an increased propensity to develop CNS
metastases compared with women with HER2-negative disease
(Pestalozzi and Brignoli, 2000; Pestalozzi et al, 2006). Results from
our study further illustrate that the incidence of CNS metastasis in
patients with HER2-positive disease is significantly higher in
patients treated with trastuzumab than in those not treated with
trastuzumab (37.8 vs 25.0%, respectively, P¼0.028). This finding
can be explained by both the known aggressive nature and by the
increased predilection to CNS metastases of HER2-positive
tumours (Dawood et al, 2008). In addition, adding trastuzumab
did not affect the development of BMs in HER2-overexpressing
breast cancer, which is associated with the poor penetration of
trastuzumab across the blood-brain barrier (BBB) and poor
activity in BMs.
Considering that trastuzumab is known not to cross the BBB
(Pestalozzi and Brignoli, 2000; Stemmler et al, 2007) and that
patients treated with trastuzumab show higher development of
BM than patients not treated with trastuzumab, introduction of
trastuzumab might not overcome the biological aggressiveness
of HER2-positive breast cancer, but may affect the clinical features
of BM by improving systemic extracranial outcomes. Actually, a
comparison of the demographic data between the pre-T and
post-T groups in our series illustrated that ‘only BMs’ (14.3 vs
2.4%, respectively, P¼0.046) is less common in the post-T group
compared with the pre-T group (Table 2). Our understanding
of these phenomena is that trastuzumab alone or in combina-
tion with chemotherapy seems to have an indirect, preventive
or delaying effect on CNS involvement, which is caused by
better systemic extracranial control with the addition of
trastuzumab.
Most importantly, our study clearly shows that adding
trastuzumab to conventional chemotherapy results in improved
BMs outcomes in terms of a much longer TTBMs (15 months vs 10
months, P¼0.035) and TTD (14.9 months vs 4.0 months,
P¼0.0005) that are independent of the trastuzumab line and
duration (Figure 2). These results are consistent with recently
published data from other studies (Bartsch et al, 2007; Dawood
et al, 2008).
Taken together, our results reveal a higher incidence of BM in
HER2-overexpressing breast cancer, but improved outcomes after
introduction of trastuzumab. This finding strongly suggests that
the level of control of extracranial disease, which is improved with
trastuzumab, is a contributing factor to the timing of development
of CNS metastases, and may be an important factor to be
considered when building predictive models. Interestingly, 12
months or more extracranial PFS was identified as an independent
prognostic factor with marked statistical significance (Po0.0001,
HR 26.301) in addition to extracranial systemic disease control at
the time of BM (P¼0.009, HR 8.368) (Table 4). Only two
patients received trastuzumab after development of BM. Therefore,
after cessation of trastuzumab treatment there is evidence of a
continuing or ‘carry-over’ effect that results in an increasing
benefit after cessation of trastuzumab. This carry-over effect can
create a more controllable extracranial condition with less tumour
burden, which is important for additional systemic treatment as
well as for active local treatment of BMs. As a result, survival from
BM can be prolonged. This explanation is also supported by the
finding that ‘two or more systemic chemotherapy regimens’ is an
independent prognostic factor on TTD (P¼0.001, HR 8.614). This
Table 3 Causes of death in 77 patients with BMs in HER2-positive
breast cancer
Pre-trastuzumab
group (n¼35)
Post-trastuzumab
group (n¼42) P-value
Brain 16 (45.7%) 25 (59.5%) 0.227 (w
2 test)
Extracranial
systemic
disease
13 (37.1%) 5 (11.9%) 0.014 (Fisher’s
exact test)
Lung 9 (25.7%) 3 (7.1%)
Liver 3 (8.6%) 1 (2.4%)
Heart 1 (2.8%) 1 (2.4%)
Unknown 7 (17.1%) 13 (28.6%)
BMs¼brain metastases.
Table 4 Cox-regression multivariate analysis on time to death from BM (TTD)
95% CI
Significance (P-value) Hazard ratio (HR) Lower Upper
Lapatinib after BM 0.040 5.069 1.080 23.784
Number of post-BM chemotherapy regimens X2 0.001 8.614 2.388 31.075
Post-BM trastuzumab 0.086 3.597 0.834 15.523
T-duration X6 months 0.792 1.168 0.369 3.694
First metastasis in brain 0.007 10.390 1.919 56.256
Poor PS (X2) 0.464 1.473 0.522 4.153
Gamma-knife surgery 0.746 1.181 0.431 3.239
Extracranial systemic disease control at the time of BM 0.009 8.368 1.697 41.264
Systemic PFS X12 months o0.0001 26.301 4.871 142.004
BM¼brain metastasis; CI¼confidence interval; PFS¼progression-free survival; PS¼performance status; T-duration¼duration of trastuzumab treatment.
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important role and should be considered even in CNS metastases,
because extracranial systemic control is a main contributing factor
for predicting survival. It is commonly believed that most patients
with BMs from advanced breast cancer do not die from cerebral
progression, but rather from progression of systemic disease. This
was apparently the major limiting factor in the survival of women
before the trastuzumab period, and since the introduction of
trastuzumab, the proportion of patients with controlled systemic
disease dying from brain lesions has grown (Kirsch et al 2005; Lin
and Winer, 2007). Apparently, death from progression of systemic
disease was more common in the pre-T than in the post-T group
(37.1 vs 11.9%, respectively, P¼0.014) (Table 3). As shown in our
study, it should be assumed that the impact on TTD stems from
the control of extracranial systemic disease, rather than the control
of brain lesions.
Further, it is important to be very cautious when stopping
trastuzumab treatment or switching to other drugs, because it is
difficult to identify cases of trastuzumab resistance.
Despite the emerging role of trastuzumab and the development
of local treatments, such as SRS, including GKS, the overall
outcome still needs to be improved. According to our earlier
report, in which a prognostic model was suggested, TTD extended
up to 49 months in cases of patients with no risk factor (good PS,
HER2 negativity and additional systemic chemotherapy after BM)
(Park et al, 2009). Considering TTD was merely 14.9 months even
in post-T period, and lapatinib treatment was identified as an
independent prognostic factor in Cox-regression model (P¼0.040,
HR 5.069) in this study (Table 4), new therapeutic strategies for
BM in HER2-positive breast cancer are urgently needed and
lapatinib may be a good therapeutic option in these cases.
The interpretations from this study have limitations. First of all,
this is a retrospective single institutional study with a hetero-
geneous group of patients and treatments. However, this study
population has some obstacles to develop a prospective rando-
mised trial, such as relatively low prevalence, the urgent need for
immediate supportive care and approval of the ethical problem to
omit standard treatment. Taking allowance for these obstacles, this
study has powerful value in providing guidelines for this particular
clinical setting.
In conclusion, the administration of trastuzumab in the
treatment of HER2-positive breast cancer results in prolonged
TTBM and TTD from BM, even after development of BM.
Extracranial systemic disease control at the time of BMs and
durable prolongation of extracranial systemic disease are the main
independent prognostic factors for predicting survival with BM.
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